If you have been reading about SR9009 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-05. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
== Atrocities and illegal activities == The Selous Scouts had a reputation for brutality. The unit conducted a number of atrocities against villages that were believed to have collaborated with the guerrillas. Members of the units also poached ivory, smuggled guns and beat and killed civilians. During attacks into Botswana, the Selous Scouts committed arson and abducted civilians. The use of insurgent uniforms and civilian clothing by the Selous Scouts may also have violated the 1907 Hague Convention and the Geneva Conventions which prohibit military personnel from wearing enemy uniforms in most circumstances and require that they clearly distinguish themselves from civilians. Some of the actions undertaken by the Selous Scouts were illegal under Rhodesian law. Selous Scout teams at times attacked Rhodesian Security Forces units and white farms in attempts to persuade local civilians that they were actually insurgents. Another tactic involved repeatedly calling in air strikes and fireforce attacks on insurgents after they had left a specific kraal leading the insurgents to kill innocent civilians in the kraal because they suspected civilians of informing on their positions; it was intended that this would sow divisions between the insurgents and civilians. The Selous Scouts also labelled insurgents as traitors to the insurgent cause and then publicly killed them leading to "disillusionment and bewilderment" among local civilians; this led to several murder investigations being opened into members of the unit.
Ants form symbiotic associations with a range of species, including other ant species, other insects, plants, and fungi. They also are preyed on by many animals and even certain fungi. Some arthropod species spend part of their lives within ant nests, either preying on ants, their larvae, and eggs, consuming the food stores of the ants, or avoiding predators. These inquilines may bear a close resemblance to ants. The nature of this ant mimicry (myrmecomorphy) varies, with some cases involving Batesian mimicry, where the mimic reduces the risk of predation. Others show Wasmannian mimicry, a form of mimicry seen only in inquilines.
== Early life and education == Schumer was born on June 1, 1981, on the Upper East Side of Manhattan, New York City, to Sandra Jane (née Jones, or Johns) and Gordon David Schumer, who owned a baby furniture company. Schumer's father was born to a Jewish family from Ukraine. She is a second cousin, once removed, of U.S. Senator and Senate Minority Leader Chuck Schumer. Her mother is from a Protestant background and has deep New England roots, and converted to Judaism before her marriage. Schumer was raised Jewish and says she had to deal with antisemitism as a child, but is not observant as an adult. Her mother is of Puritan ancestry dating back to the colonial-era Massachusetts Bay Colony. In 2017, as a guest on Finding Your Roots, Schumer learned that in 1704, three children from her ancestor Thomas Tarbell's family were captured at Groton, Massachusetts, in a French-Abenaki raid and taken to Montreal. The girl was ransomed by a French-Canadian family and ultimately joined a French Catholic convent; the two boys were each adopted by Mohawk families at Kahnawake and became thoroughly assimilated. They married Mohawk women and some of their descendants became chiefs. There are still Mohawk by the surname Tarbell in Kahnawake and Akwesasne, another village reserve on the St. Lawrence River founded by the brothers. Through the success of her father's furniture company in Manhattan, Schumer's household was wealthy during her early years. When she was nine years old her father's business failed and he went bankrupt. He was subsequently diagnosed with multiple sclerosis.
With an estimated 50 million people in 2020, Colombia is the third-most populous country in Latin America, after Brazil and Mexico. At the beginning of the 20th century, Colombia's population was approximately 4 million. Since the early 1970s, Colombia has experienced steady declines in its fertility, mortality, and population growth rates. The population growth rate for 2016 is estimated to be 0.9%. About 26.8% of the population were 15 years old or younger, 65.7% were between 15 and 64 years old, and 7.4% were over 65 years old. The proportion of older persons in the total population has begun to increase substantially. Colombia is projected to have a population of 55.3 million by 2050. Estimates for the population of the area that is now Colombia range between 2.5 and 12 million people in 1500; estimates between the extremes include figures of 6 and 7 million. With the Spanish conquest, the region's population had collapsed to around 1.2 million people in 1600, for an estimated decrease of 52–90%. By the end of the colonial period, it had declined further to around 800,000; it began rising in the early 19th century to around 1.4 million, where it would drop again in the Colombian War of Independence to between 1 and 1.2 million. The country's population did not recover to pre-conquest levels until the 1940s, nearly 450 years after its 16th-century peak. The population is concentrated in the Andean highlands and along the Caribbean coast, also the population densities are generally higher in the Andean region.
Sources: en.wikipedia.org
knockin (KI) A genetic engineering method in which one or more novel genes are inserted into an organism's genome, particularly when targeted to a specific locus, or in which one or more existing genes are replaced by or substituted with novel genes. This is in contrast to a knockout, in which a gene is deleted or completely inactivated.
=== Holland Sweetener Company === A joint venture of DSM and Tosoh, the Holland Sweetener Company manufactured aspartame using the enzymatic process developed by Toyo Soda (Tosoh) and sold as the brand Sanecta. Additionally, they developed a combination aspartame-acesulfame salt under the brand name Twinsweet. They left the sweetener industry in 2006, because "global aspartame markets are facing structural oversupply, which has caused worldwide strong price erosion over the last five years", making the business "persistently unprofitable".
International Chemical Safety Card 1262 (2-methylpentane) Material Safety Data Sheet for Hexane National Pollutant Inventory – n-hexane fact sheet Phytochemica l database entry Center for Disease Control and Prevention Warning from National Safety Council "COMMON CHEMICAL AFFECTS AUTO MECHANICS" Australian National Pollutant Inventory (NPI) page "EPA does not consider n-hexane classifiable as a human carcinogen." Federal Register / Vol. 66, No. 71 / Thursday, 12 April 2001 / Rules and Regulations
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.